Brentuximab Vedotin

(asked on 7th February 2017) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what steps his Department is taking to ensure relapsed and refractory Hodgkin lymphoma patients continue to have access to brentuximab vedotin.


This question was answered on 15th February 2017

Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is appraising Brentuximab for this indication and recently consulted stakeholders on its draft recommendations. Brentuximab is currently available to NHS patients with relapsed and refractory Hodgkin lymphoma through the Cancer Drugs Fund.

Reticulating Splines